A Phase Ib/II Study of MEK162 plus Panitumumab in Patients with Metastatic Colorectal Cancer

Full Title

A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation Study of MEK162 in Combination with Panitumumab in Adult Patients with Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer


Panitumumab is an anticancer drug used to treat colorectal cancer. It works by binding to and blocking a protein involved in cancer growth called the epidermal growth factor receptor (EGFR). In this study, researchers want to evaluate the safety and effectiveness of giving the investigational drug MEK162 in combination with panitumumab in several groups of patients with metastatic colorectal cancer, including patients whose tumors previously responded to panitumumab or cetuximab (another EGFR inhibitor) and then later started to grow again.

MEK162 works by inhibiting MEK1/2, a protein which drives cancer growth. Panitumumab MEK162 is taken orally (by mouth), while panitumumab is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic colorectal cancer that has continued to grow despite at least two prior regimens of chemotherapy. The study will include patients whose tumors initially responded to panitumumab or cetuximab and then started to grow again.
  • Patients must have recovered from the serious side effects of prior therapies.
  • Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Rona Yaeger at 646-888-5109.